Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ART24 in Recently Cured CDI
NCT04891965Phase 1Completed
- Sponsor
- Adiso Therapeutics
- Start
- Feb 2020
- Primary completion
- Jul 2022
- Modality
- Live Biotherapeutic Products
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial of ART24 in Clostridioides difficile infection (CDI) (4 cohorts), sponsored by Adiso Therapeutics. Primary endpoints: Treatment-Emergent Adverse Events at Week 16 and Change in Clinical Laboratory Tests, Vital Signs, Physical Examination at Week 16. Started Feb 2020; status: completed.
02
Drugs
ART24
03
Conditions
Clostridioides difficile infection (CDI)
Beyond the preview
Go deeper on NCT04891965.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04891965.